QUETIAPINE AS COMBINATION TREATMENT WITH CITALOPRAM IN UNIPOLAR DEPRESSION WITH PROMINENT SOMATIC SYMPTOMS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDYReportar como inadecuado




QUETIAPINE AS COMBINATION TREATMENT WITH CITALOPRAM IN UNIPOLAR DEPRESSION WITH PROMINENT SOMATIC SYMPTOMS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Psychiatria Danubina, Vol.25 No.3 September 2013. -

Background: Patients with major depressive disorder MDD accompanied by physical symptoms may be less responsive to

antidepressant treatment. Quetiapine has been evaluated in the treatment of bipolar depression and has been recently approved as

an add-on therapy for unipolar depression. Less is known about the efficacy of combination therapies in patients suffering from

MDD with somatic symptoms. The aim of the present study was to evaluate the efficacy of quetiapine as adjunctive therapy to the

SSRI citalopram in patients with MDD and somatic complaints.

Subjects and methods: 41 inpatients with nonpsychotic DSM-IV MDD experiencing significant symptoms of somatic distress as

defined by a baseline score on the SCL-90-R somatization subscale greater one standard deviation above adult nonpatient norms

were randomly assigned to receive either citalopram 40 mg-day plus placebo n=20 or citalopram 40 mg-day plus quetiapine, 300

to 600 mg-day n=21 for 6 weeks. The primary outcome measure was the Hamilton Depression Rating Scale HDRS score.

Results: Mean changes in HDRS scores from baseline to week 6 using last-observation-carried-forward methods were -12.3±6.2

and -10.7±5.1 in the citalopram-quetiapine and citalopram-placebo group, respectively. Remission rates were significant higher in

the citalopram-quetiapine-group 41.1% than in the citalopram-placebo-group 26.3%, respectively.

Conclusions: Although quetiapine as add-on to citalopram did not separate statistically from placebo on the HDRS score in

improving depressive symptoms and somatic symptoms in patients with MDD and prominent somatic complaints, higher remission

rates and other second outcome parameters showed advantages for quetiapine. Larger, double-blind, placebo-controlled trials of

quetiapine as augmentation therapy in MDD with somatic symptoms are warranted.

antidepressants – citalopram - major depression – quetiapine - somatic symptoms



Autor: Arnim Quante - ; Department of Psychiatry and Psychotherapy, Charité – University Medicine Berlin, Campus Benjamin Franklin, B

Fuente: http://hrcak.srce.hr/



DESCARGAR PDF




Documentos relacionados